Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Inclusion Criteria: * Male or female \>= 18 years of age * Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas * The participant is scheduled for standard of care surgical tumor resection * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial Exclusion Criteria: * Male or female \< 18 years of age * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data * Not medically cleared for surgery * Individuals who cannot tolerate MRI scan or PET/CT scan * Pregnant or breast-feeding women * Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate \[GFR\] can be use in place of creatinine or creatinine clearance \[CrCl\]) =\< 1.5 X institutional upper limit of normal (ULN) OR \>= 60mL/min for subjects with creatinine levels \> 1.5 X institutional ULN * Creatinine clearance should be calculated per institutional standard * Serum total bilirubin: =\< 1.5 X institutional ULN OR direct bilirubin =\< institutional ULN for subjects with total bilirubin levels \> 1.5 institutional ULN * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 X institutional ULN OR =\< 5 X institutional ULN for subjects with Gilberts syndrome * Albumin \>= 2.5 mg/dL * Patients with splenic dysfunction or post splenectomy * Any abnormalities that would be a contraindication to gadolinium-based contrast agent